ACR appropriateness criteria permanent source brachytherapy for prostate cancer

Brian J. Davis, Al V. Taira, Paul L. Nguyen, Dean G. Assimos, Anthony V. D'Amico, Alexander R. Gottschalk, Gary S. Gustafson, Sameer R. Keole, Stanley L. Liauw, Shane Lloyd, Patrick W. McLaughlin, Benjamin Movsas, Bradley R. Prestidge, Timothy N. Showalter, Neha Vapiwala

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Purpose: To provide updated American College of Radiology (ACR) appropriateness criteria for transrectal ultrasound-guided transperineal interstitial permanent source brachytherapy. Methods and Materials: The ACR appropriateness criteria are evidence-based guidelines for specific clinical conditions that are reviewed every 3 years by a multidisciplinary expert panel. The guideline development and review include an extensive analysis of current medical literature from peer reviewed journals and the application of a well-established consensus methodology (modified Delphi) to rate the appropriateness of imaging and treatment procedures by the panel. In those instances where evidence is lacking or not definitive, expert opinion may be used to recommend imaging or treatment. Results: Permanent prostate brachytherapy (PPB) is a treatment option for appropriately selected patients with localized prostate cancer with low to very high risk disease. PPB monotherapy remains an appropriate and effective curative treatment for low-risk prostate cancer patients demonstrating excellent long-term cancer control and acceptable morbidity. PPB monotherapy can be considered for select intermediate-risk patients with multiparametric MRI useful in evaluation of such patients. High-risk patients treated with PPB should receive supplemental external beam radiotherapy (EBRT) along with androgen deprivation. Similarly, patients with involved pelvic lymph nodes may also be considered for such combined treatment but reported long-term outcomes are limited. Computed tomography-based postimplant dosimetry completed within 60 days of PPB is essential for quality assurance. PPB may be considered for treatment of local recurrence after EBRT but is associated with an increased risk of toxicity. Conclusions: Updated appropriateness criteria for patient evaluation, selection, treatment, and postimplant dosimetry are given. These criteria are intended to be advisory only with the final responsibility for patient care residing with the treating clinicians.

Original languageEnglish (US)
JournalBrachytherapy
DOIs
StateAccepted/In press - Sep 22 2016

Fingerprint

Brachytherapy
Radiology
Prostatic Neoplasms
Prostate
Therapeutics
Radiotherapy
Guidelines
Expert Testimony
Patient Selection
Androgens
Patient Care
Lymph Nodes
Tomography
Morbidity
Recurrence
Neoplasms

Keywords

  • Brachytherapy
  • Guideline
  • Prostate cancer
  • Radiation therapy
  • Radiotherapy
  • Standard

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

Davis, B. J., Taira, A. V., Nguyen, P. L., Assimos, D. G., D'Amico, A. V., Gottschalk, A. R., ... Vapiwala, N. (Accepted/In press). ACR appropriateness criteria permanent source brachytherapy for prostate cancer. Brachytherapy. https://doi.org/10.1016/j.brachy.2016.10.002

ACR appropriateness criteria permanent source brachytherapy for prostate cancer. / Davis, Brian J.; Taira, Al V.; Nguyen, Paul L.; Assimos, Dean G.; D'Amico, Anthony V.; Gottschalk, Alexander R.; Gustafson, Gary S.; Keole, Sameer R.; Liauw, Stanley L.; Lloyd, Shane; McLaughlin, Patrick W.; Movsas, Benjamin; Prestidge, Bradley R.; Showalter, Timothy N.; Vapiwala, Neha.

In: Brachytherapy, 22.09.2016.

Research output: Contribution to journalArticle

Davis, BJ, Taira, AV, Nguyen, PL, Assimos, DG, D'Amico, AV, Gottschalk, AR, Gustafson, GS, Keole, SR, Liauw, SL, Lloyd, S, McLaughlin, PW, Movsas, B, Prestidge, BR, Showalter, TN & Vapiwala, N 2016, 'ACR appropriateness criteria permanent source brachytherapy for prostate cancer', Brachytherapy. https://doi.org/10.1016/j.brachy.2016.10.002
Davis BJ, Taira AV, Nguyen PL, Assimos DG, D'Amico AV, Gottschalk AR et al. ACR appropriateness criteria permanent source brachytherapy for prostate cancer. Brachytherapy. 2016 Sep 22. https://doi.org/10.1016/j.brachy.2016.10.002
Davis, Brian J. ; Taira, Al V. ; Nguyen, Paul L. ; Assimos, Dean G. ; D'Amico, Anthony V. ; Gottschalk, Alexander R. ; Gustafson, Gary S. ; Keole, Sameer R. ; Liauw, Stanley L. ; Lloyd, Shane ; McLaughlin, Patrick W. ; Movsas, Benjamin ; Prestidge, Bradley R. ; Showalter, Timothy N. ; Vapiwala, Neha. / ACR appropriateness criteria permanent source brachytherapy for prostate cancer. In: Brachytherapy. 2016.
@article{fcc62a12536e435bb43f101cdd9ca94a,
title = "ACR appropriateness criteria permanent source brachytherapy for prostate cancer",
abstract = "Purpose: To provide updated American College of Radiology (ACR) appropriateness criteria for transrectal ultrasound-guided transperineal interstitial permanent source brachytherapy. Methods and Materials: The ACR appropriateness criteria are evidence-based guidelines for specific clinical conditions that are reviewed every 3 years by a multidisciplinary expert panel. The guideline development and review include an extensive analysis of current medical literature from peer reviewed journals and the application of a well-established consensus methodology (modified Delphi) to rate the appropriateness of imaging and treatment procedures by the panel. In those instances where evidence is lacking or not definitive, expert opinion may be used to recommend imaging or treatment. Results: Permanent prostate brachytherapy (PPB) is a treatment option for appropriately selected patients with localized prostate cancer with low to very high risk disease. PPB monotherapy remains an appropriate and effective curative treatment for low-risk prostate cancer patients demonstrating excellent long-term cancer control and acceptable morbidity. PPB monotherapy can be considered for select intermediate-risk patients with multiparametric MRI useful in evaluation of such patients. High-risk patients treated with PPB should receive supplemental external beam radiotherapy (EBRT) along with androgen deprivation. Similarly, patients with involved pelvic lymph nodes may also be considered for such combined treatment but reported long-term outcomes are limited. Computed tomography-based postimplant dosimetry completed within 60 days of PPB is essential for quality assurance. PPB may be considered for treatment of local recurrence after EBRT but is associated with an increased risk of toxicity. Conclusions: Updated appropriateness criteria for patient evaluation, selection, treatment, and postimplant dosimetry are given. These criteria are intended to be advisory only with the final responsibility for patient care residing with the treating clinicians.",
keywords = "Brachytherapy, Guideline, Prostate cancer, Radiation therapy, Radiotherapy, Standard",
author = "Davis, {Brian J.} and Taira, {Al V.} and Nguyen, {Paul L.} and Assimos, {Dean G.} and D'Amico, {Anthony V.} and Gottschalk, {Alexander R.} and Gustafson, {Gary S.} and Keole, {Sameer R.} and Liauw, {Stanley L.} and Shane Lloyd and McLaughlin, {Patrick W.} and Benjamin Movsas and Prestidge, {Bradley R.} and Showalter, {Timothy N.} and Neha Vapiwala",
year = "2016",
month = "9",
day = "22",
doi = "10.1016/j.brachy.2016.10.002",
language = "English (US)",
journal = "Brachytherapy",
issn = "1538-4721",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - ACR appropriateness criteria permanent source brachytherapy for prostate cancer

AU - Davis, Brian J.

AU - Taira, Al V.

AU - Nguyen, Paul L.

AU - Assimos, Dean G.

AU - D'Amico, Anthony V.

AU - Gottschalk, Alexander R.

AU - Gustafson, Gary S.

AU - Keole, Sameer R.

AU - Liauw, Stanley L.

AU - Lloyd, Shane

AU - McLaughlin, Patrick W.

AU - Movsas, Benjamin

AU - Prestidge, Bradley R.

AU - Showalter, Timothy N.

AU - Vapiwala, Neha

PY - 2016/9/22

Y1 - 2016/9/22

N2 - Purpose: To provide updated American College of Radiology (ACR) appropriateness criteria for transrectal ultrasound-guided transperineal interstitial permanent source brachytherapy. Methods and Materials: The ACR appropriateness criteria are evidence-based guidelines for specific clinical conditions that are reviewed every 3 years by a multidisciplinary expert panel. The guideline development and review include an extensive analysis of current medical literature from peer reviewed journals and the application of a well-established consensus methodology (modified Delphi) to rate the appropriateness of imaging and treatment procedures by the panel. In those instances where evidence is lacking or not definitive, expert opinion may be used to recommend imaging or treatment. Results: Permanent prostate brachytherapy (PPB) is a treatment option for appropriately selected patients with localized prostate cancer with low to very high risk disease. PPB monotherapy remains an appropriate and effective curative treatment for low-risk prostate cancer patients demonstrating excellent long-term cancer control and acceptable morbidity. PPB monotherapy can be considered for select intermediate-risk patients with multiparametric MRI useful in evaluation of such patients. High-risk patients treated with PPB should receive supplemental external beam radiotherapy (EBRT) along with androgen deprivation. Similarly, patients with involved pelvic lymph nodes may also be considered for such combined treatment but reported long-term outcomes are limited. Computed tomography-based postimplant dosimetry completed within 60 days of PPB is essential for quality assurance. PPB may be considered for treatment of local recurrence after EBRT but is associated with an increased risk of toxicity. Conclusions: Updated appropriateness criteria for patient evaluation, selection, treatment, and postimplant dosimetry are given. These criteria are intended to be advisory only with the final responsibility for patient care residing with the treating clinicians.

AB - Purpose: To provide updated American College of Radiology (ACR) appropriateness criteria for transrectal ultrasound-guided transperineal interstitial permanent source brachytherapy. Methods and Materials: The ACR appropriateness criteria are evidence-based guidelines for specific clinical conditions that are reviewed every 3 years by a multidisciplinary expert panel. The guideline development and review include an extensive analysis of current medical literature from peer reviewed journals and the application of a well-established consensus methodology (modified Delphi) to rate the appropriateness of imaging and treatment procedures by the panel. In those instances where evidence is lacking or not definitive, expert opinion may be used to recommend imaging or treatment. Results: Permanent prostate brachytherapy (PPB) is a treatment option for appropriately selected patients with localized prostate cancer with low to very high risk disease. PPB monotherapy remains an appropriate and effective curative treatment for low-risk prostate cancer patients demonstrating excellent long-term cancer control and acceptable morbidity. PPB monotherapy can be considered for select intermediate-risk patients with multiparametric MRI useful in evaluation of such patients. High-risk patients treated with PPB should receive supplemental external beam radiotherapy (EBRT) along with androgen deprivation. Similarly, patients with involved pelvic lymph nodes may also be considered for such combined treatment but reported long-term outcomes are limited. Computed tomography-based postimplant dosimetry completed within 60 days of PPB is essential for quality assurance. PPB may be considered for treatment of local recurrence after EBRT but is associated with an increased risk of toxicity. Conclusions: Updated appropriateness criteria for patient evaluation, selection, treatment, and postimplant dosimetry are given. These criteria are intended to be advisory only with the final responsibility for patient care residing with the treating clinicians.

KW - Brachytherapy

KW - Guideline

KW - Prostate cancer

KW - Radiation therapy

KW - Radiotherapy

KW - Standard

UR - http://www.scopus.com/inward/record.url?scp=85007609351&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85007609351&partnerID=8YFLogxK

U2 - 10.1016/j.brachy.2016.10.002

DO - 10.1016/j.brachy.2016.10.002

M3 - Article

JO - Brachytherapy

JF - Brachytherapy

SN - 1538-4721

ER -